MA33412B1 - Compositions adjuvantes contenant un agent d'isotonicité non ionique - Google Patents

Compositions adjuvantes contenant un agent d'isotonicité non ionique

Info

Publication number
MA33412B1
MA33412B1 MA34506A MA34506A MA33412B1 MA 33412 B1 MA33412 B1 MA 33412B1 MA 34506 A MA34506 A MA 34506A MA 34506 A MA34506 A MA 34506A MA 33412 B1 MA33412 B1 MA 33412B1
Authority
MA
Morocco
Prior art keywords
isotonicity agent
compositions containing
adjuvant compositions
ionic isotonicity
ionic
Prior art date
Application number
MA34506A
Other languages
Arabic (ar)
English (en)
Inventor
Veronique Henderickx
Dominique Ingrid Lemoine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33412(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA33412B1 publication Critical patent/MA33412B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions adjuvantes et immunogènes renfermant un agoniste du TLR-4 et une saponine dans une formulation liposomique et un agent d'isotonicité non ionique, la concentration en chlorure de sodium ou la force ionique étant inférieure à 100 mM.
MA34506A 2009-06-10 2010-06-08 Compositions adjuvantes contenant un agent d'isotonicité non ionique MA33412B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
PCT/EP2010/058017 WO2010142685A1 (fr) 2009-06-10 2010-06-08 Compositions adjuvantes contenant un agent d'isotonicité non ionique

Publications (1)

Publication Number Publication Date
MA33412B1 true MA33412B1 (fr) 2012-07-03

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34506A MA33412B1 (fr) 2009-06-10 2010-06-08 Compositions adjuvantes contenant un agent d'isotonicité non ionique

Country Status (31)

Country Link
US (2) US20120087976A1 (fr)
EP (1) EP2440242B1 (fr)
JP (3) JP5647677B2 (fr)
KR (1) KR101473686B1 (fr)
CN (2) CN102458457B (fr)
AU (1) AU2010257538B2 (fr)
BR (1) BRPI1012890B1 (fr)
CA (1) CA2764421C (fr)
CL (1) CL2011003113A1 (fr)
CO (1) CO6440528A2 (fr)
CY (1) CY1115522T1 (fr)
DK (1) DK2440242T3 (fr)
DO (1) DOP2011000346A (fr)
EA (1) EA024074B1 (fr)
ES (1) ES2494442T3 (fr)
GB (1) GB0910046D0 (fr)
HR (1) HRP20140792T1 (fr)
IL (1) IL216231A0 (fr)
MA (1) MA33412B1 (fr)
MX (1) MX2011013162A (fr)
MY (1) MY159819A (fr)
NZ (1) NZ596503A (fr)
PE (1) PE20120319A1 (fr)
PL (1) PL2440242T3 (fr)
PT (1) PT2440242E (fr)
RS (1) RS53550B1 (fr)
SG (1) SG176638A1 (fr)
SI (1) SI2440242T1 (fr)
SM (1) SMT201400134B (fr)
UA (1) UA104888C2 (fr)
WO (1) WO2010142685A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2975024T3 (pl) 2009-06-10 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Związki tetracykliczne
BR112013003879B1 (pt) 2010-08-20 2020-12-22 Chugai Seiyaku Kabushiki Kaisha composição compreendendo compostos tetracíclicos e formulação oralmente administrável que a compreende
CA2819297A1 (fr) * 2010-12-14 2012-06-21 Glaxosmithkline Biologicals S.A. Composition antigenique de mycobacterium
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
KR102242875B1 (ko) * 2014-03-25 2021-04-20 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 리프리젠티드 바이 더 세크리터리 오브 더 아미 모노포스포릴 지질 a (mpla)-함유 리포솜 조성물 및 사포닌을 포함하는 무독성 아주반트 제제
CN106458967A (zh) 2014-04-25 2017-02-22 中外制药株式会社 四环化合物的新结晶
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
CA3045952A1 (fr) * 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Nouveau procede
IL292991A (en) 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
JP2020521781A (ja) 2017-05-30 2020-07-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リポソームに内包されたｒｎａを製造する方法
AU2018350887A1 (en) * 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3717005A1 (fr) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Extraction de saponine
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3815688B1 (fr) 2018-06-29 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique contenant un médicament basique faiblement soluble
AU2019337018B2 (en) 2018-09-04 2024-03-07 Chugai Seiyaku Kabushiki Kaisha Method of producing tetracyclic compound
WO2020109365A1 (fr) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
EP4021407A1 (fr) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Procédé de fabrication de nanoparticules lipidiques mélangées par jet
EP4570269A4 (fr) * 2023-03-15 2025-10-22 United Immunity Co Ltd Particule lipidique
WO2025180443A1 (fr) * 2024-02-29 2025-09-04 Immunadd Inc. Composition d'adjuvant, composition pharmaceutique la comprenant, et méthode de prévention ou de traitement d'une maladie provoquée par une infection virale, une infection bactérienne, une infection protozoaire ou un cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
EP0689454B2 (fr) * 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
DK1075276T3 (da) * 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1829887B1 (fr) * 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Desoxynucleotides cpg a brin unique a utiliser comme adjuvant
US9486515B2 (en) * 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DK2114993T3 (da) 2007-01-15 2012-10-22 Glaxosmithkline Biolog Sa Vaccine
MX2009007572A (es) 2007-01-15 2009-10-13 Glaxosmithkline Biolog Sa Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
CA2687632C (fr) * 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Composition lyophilisee d'antigene
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
AU2010257538A1 (en) 2011-12-08
EP2440242B1 (fr) 2014-06-25
HRP20140792T1 (hr) 2014-10-10
WO2010142685A1 (fr) 2010-12-16
PL2440242T3 (pl) 2014-11-28
UA104888C2 (uk) 2014-03-25
KR101473686B1 (ko) 2014-12-18
RS53550B1 (sr) 2015-02-27
KR20120031497A (ko) 2012-04-03
PT2440242E (pt) 2014-08-29
DK2440242T3 (da) 2014-09-01
CO6440528A2 (es) 2012-05-15
AU2010257538B2 (en) 2016-10-20
CN104367997B (zh) 2019-01-22
CA2764421A1 (fr) 2010-12-16
MY159819A (en) 2017-02-15
CL2011003113A1 (es) 2012-08-31
CY1115522T1 (el) 2017-01-04
CN102458457B (zh) 2015-05-20
JP2015042646A (ja) 2015-03-05
EP2440242A1 (fr) 2012-04-18
CN104367997A (zh) 2015-02-25
EA201190286A1 (ru) 2012-06-29
BRPI1012890A2 (pt) 2018-02-27
CA2764421C (fr) 2016-12-06
NZ596503A (en) 2013-08-30
JP5977789B2 (ja) 2016-08-24
EA024074B1 (ru) 2016-08-31
GB0910046D0 (en) 2009-07-22
SG176638A1 (en) 2012-01-30
BRPI1012890B1 (pt) 2022-03-22
DOP2011000346A (es) 2012-01-15
ES2494442T3 (es) 2014-09-15
MX2011013162A (es) 2012-01-30
JP2016193912A (ja) 2016-11-17
IL216231A0 (en) 2012-01-31
PE20120319A1 (es) 2012-04-16
JP5647677B2 (ja) 2015-01-07
US20120087976A1 (en) 2012-04-12
CN102458457A (zh) 2012-05-16
JP6261647B2 (ja) 2018-01-17
JP2012529464A (ja) 2012-11-22
US20180021417A1 (en) 2018-01-25
SI2440242T1 (sl) 2014-09-30
SMT201400134B (it) 2014-11-10

Similar Documents

Publication Publication Date Title
MA33412B1 (fr) Compositions adjuvantes contenant un agent d'isotonicité non ionique
MX2007007305A (es) Composiciones para limpiar la piel que se retiran por enjuague o con un pano.
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
NO20082538L (no) Stabiliserte lantankarbonatsammensetninger
EP2019857A4 (fr) Combinaison adjuvante synergique d'anticorps agoniste cd40/interféron de type 1, conjugués contenant une telle combinaison et utilisation en tant qu'agent thérapeutique pour améliorer l'immunite cellulaire
BRPI0515316A (pt) compostos de imidazoquinolina
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
WO2007090822A3 (fr) Formulation pharmaceutique destinée à des aérosols, contenant au moins deux agents actifs et au moins une substance tensioactive
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
NO20064584L (no) Tetrahydropyridoindolderivater
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
JO2945B1 (en) Methods of giving prolonged hypoglycemic agents
ATE544444T1 (de) Zusammensetzungen für die nasale abgabe
JP2020111603A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
TW200605872A (en) Alcohol-metabolism enhancing composition and ingesta containing the same
MA35158B1 (fr) Formulations topiques de type suspension comprenant un depsipeptide cyclique
MA30711B1 (fr) Sels d'ethers benzimidazolyle pyridyle et formulations associees
TW200616647A (en) Progression inhibitor for disease attributed to abnormal accumulation of liver fat
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
JP2018193403A (ja) シリコーンハイドロゲルコンタクトレンズ用点眼剤
JP2010043047A5 (fr)
BRPI0415576A (pt) composição para cuidados pessoais contendo um tensoativo detersivo, um componente anticaspa e tensoativos de cetoamida
MA30561B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur préparation, compositions les contenant et utilisation.
UA101304C2 (ru) Способы введения гипогликемических средств продленного действия